CERUS CORP

Overview

Compare with ORTHOPEDIATRICS CORP, LEMAITRE VASCULAR INC or TREACE MEDICAL CONCEPTS, INC., or pick any stock.

• TickerCERS on Nasdaq¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersConcord, California¹
• Incorporated inDE²
• Business address1220 Concord Avenue, Suite 600, Concord, Ca 94520²
• Filer categoryAccelerated filer²

See how the biggest companies compare on our leaderboards

We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.⁴ From its latest annual report

Corporate structure

CERUS CORP sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CERUS CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our corporate headquarters, which includes our principal executive offices, is located in Concord, California. We lease this facility, which includes 84,631 square feet and includes laboratory space for blood safety research and supports general administrative, marketing and technical support functions. Of the 84,631 square feet, we ceased using approximately 15,000 square feet of rentable area of corporate office building in the third quarter of 2023. We are currently marketing our vacant space, though there continues to be more supply than demand for office space in the San Francisco Bay Area. We also lease an office facility in Amersfoort, the Netherlands, which is used for selling and administrative functions. We believe that our current and future facilities will be adequate for the foreseeable future.

Item 2 of the 10-K filed Mar 2, 2026.⁴

Leadership

Who has led CERUS CORP, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerVivek K. Jayaraman Jul 20, 2026 to now¹³
• Chief executive officerWilliam Mariner Greenman Apr 20, 2011 to Jul 20, 2026¹⁴
• PresidentCaspar Jan Hogeboom Mar 5, 2013 to Dec 15, 2015¹⁵
• PresidentWilliam Mariner Greenman Oct 4, 2006 to Mar 5, 2013¹⁶
• Chief financial officerKevin Dennis Green Mar 5, 2013 to now¹⁷
• Chief operating officerVivek K. Jayaraman Dec 28, 2020 to now¹⁸

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• Cerus Europe B.V Netherlands³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

1. Jul 30, 20268-K Results of operations⁴³
2. Jul 20, 2026New chief executive Vivek K. Jayaraman becomes CEO¹³
3. Jul 10, 20268-K Executive or director change⁴⁴
4. Jun 8, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation⁴⁵
5. Jun 3, 20268-K Executive or director change; Shareholder vote⁴⁶
6. Apr 30, 20268-K Results of operations⁴⁷
7. Apr 21, 20268-K Executive or director change⁴⁸
8. Mar 16, 20268-K Executive or director change⁴⁹
9. Mar 2, 20268-K Results of operations⁵⁰
10. Jan 23, 20268-K Executive or director change⁵¹
11. Jan 12, 20268-K Results of operations⁵²
12. Nov 6, 20258-K Results of operations⁵³
13. Aug 5, 20258-K Results of operations⁵⁴
14. Apr 20, 2011New chief executive William Mariner Greenman becomes CEO¹⁴

Calendar

Coming up

1. Nov 2, 2026 · After the closeReports results for the quarter ending Sep/2026⁵⁵

When it reported results

1. Jul 30, 2026Reported quarterly or annual results⁴³
2. Apr 30, 2026Reported quarterly or annual results⁴⁷
3. Mar 2, 2026Reported quarterly or annual results⁵⁰
4. Jan 12, 2026Reported quarterly or annual results⁵²
5. Nov 6, 2025Reported quarterly or annual results⁵³
6. Aug 5, 2025Reported quarterly or annual results⁵⁴
7. May 1, 2025Reported quarterly or annual results⁵⁶
8. Feb 20, 2025Reported quarterly or annual results⁵⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

314 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 161 insider forms, 30 large holders, 56 other. The latest 20:

1. Aug 17, 2026144 EDGAR
2. Aug 17, 20264 EDGAR
3. Aug 14, 2026SCHEDULE 13G/A EDGAR
4. Aug 14, 2026SCHEDULE 13G/A EDGAR
5. Aug 13, 2026SCHEDULE 13G/A EDGAR
6. Jul 30, 2026S-8 EDGAR
7. Jul 30, 202610-Q EDGAR
8. Jul 30, 20268-K EDGAR
9. Jul 20, 20264 EDGAR
10. Jul 16, 2026144 EDGAR
11. Jul 10, 20268-K EDGAR
12. Jul 2, 20264 EDGAR
13. Jul 2, 20264 EDGAR
14. Jul 2, 20264 EDGAR
15. Jul 2, 20264 EDGAR
16. Jun 11, 20264 EDGAR
17. Jun 9, 2026144 EDGAR
18. Jun 8, 20268-K EDGAR
19. Jun 3, 20268-K EDGAR
20. Jun 2, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

105 open-market trades by officers, directors and large owners since October 2021: 12 buys and 93 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• ARK Investment Management LLCSCHEDULE 13G/A, 9 filings Feb 9, 2022 to Aug 14, 2026⁵⁸
• BAKER BROS. ADVISORS LPSCHEDULE 13G/A, 6 filings Feb 14, 2023 to Aug 14, 2026⁵⁹
• Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 2 filings Mar 24, 2026 to Aug 13, 2026⁶⁰
• VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 9, 2022 to Mar 26, 2026⁶¹
• BlackRockSC 13G/A, 3 filings Feb 1, 2022 to Jan 26, 2024⁶²
• Amova Asset Management Americas, Inc.SC 13G/A, 2 filings Feb 14, 2022 to Feb 10, 2023⁶³
• Sumitomo Mitsui Trust GroupSC 13G/A, 2 filings Feb 4, 2022 to Feb 3, 2023⁶⁴
• PRIMECAP MANAGEMENT CO/CA/SC 13G/A, 2 filings Feb 10, 2022 to Jan 9, 2023⁶⁵

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CERUS CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCERUS CORP¹
• CIK0001020214
• Employer ID (EIN)68-0262011⁴
• Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address1220 Concord Avenue, Suite 600, Concord, CA 94520¹
• Phone9252886000¹
• Shares outstanding201,524,898 as of Jul 16, 2026¹¹
• Public float$230.0M as of Jun 30, 2025⁴
• AuditorErnst & Young LLP, San Francisco, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceSep 4, 1996¹
• Filings1,510 in all: 4 (658), 8-K (254), SC 13G/A (95), 10-Q (89), CT ORDER (59), DEF 14A (29), 10-K (27), SC 13G (27)¹
  All 47 form types

  S-8 (26), 424B5 (23), DEFA14A (22), 4/A (21), 144 (20), 3 (18), UPLOAD (16), ARS (14), CORRESP (13), SD (13), S-3 (11), S-3/A (11), SCHEDULE 13G/A (9), EFFECT (6), 10-K/A (4), 3/A (4), 424B3 (4), SC 13D/A (4), PRE 14A (3), S-1/A (3), SC 13D (3), 10-K405 (2), 10-Q/A (2), 424B4 (2), 8-A12G (2), S-3MEF (2), SEC STAFF LETTER (2), 15-12G (1), 8-A12G/A (1), 8-K/A (1), DEFR14A (1), FWP (1), NTN 10K (1), POS AM (1), POSASR (1), REGDEX (1), S-1 (1), S-3ASR (1), SCHEDULE 13G (1)

• Latest filingsAnnual report (10-K) Mar 2, 2026
  Quarterly report (10-Q) Jul 30, 2026
  Proxy statement (DEF 14A) Apr 22, 2026
  Latest 8-K (8-K) Jul 30, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 2, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks CERUS CORP names in Item 1A of its 10-K filed Mar 2, 2026: 39 risks under these headings, as written.⁴

• Risks Related to Our Business and Industry
• We depend substantially upon the commercial success of the INTERCEPT Blood System for platelets, plasma and cryoprecipitation in the U.S., and our inability to successfully commercialize the INTERCEPT Blood System in the U.S. would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
• The INTERCEPT Blood System may not achieve or be able to sustain broad market adoption.
• We are exposed to risks associated with the highly concentrated market for the INTERCEPT Blood System.
• We may be unable to develop and maintain an effective and qualified U.S.-based commercial organization or educate blood centers, clinicians and hospital personnel. As a result, we may not be able to successfully educate the market on the value of pathogen reduction or commercialize our products in the U.S.
• We have very limited experience selling directly to hospitals or expertise complying with regulations governing finished biologics, and our inability to successfully commercialize the INTERCEPT Blood System for cryoprecipitation in the U.S. would have a material adverse effect on our business, financial condition, results of operations and growth prospects.
• We may be liable and we may need to withdraw our products from the market if our products harm people. We may be liable if an accident occurs in our controlled use of hazardous materials. Our insurance coverage may be inadequate to offset losses we may incur.
• A recall of our products, either voluntarily or at the direction of the FDA, the competent authorities of an EU Member State, or another governmental authority, including foreign regulatory authority or the discovery of serious safety issues with our products that leads to corrective actions, could have a significant adverse impact on us.
• If our competitors develop products superior to ours, market their products more effectively, or receive regulatory approval or certification before our products, our commercial opportunities could be reduced or be eliminated. Competitors have and may continue to file claims in order to impede the marketability of our products, regardless of the merit of such claims.
• Our platelet and plasma products and product candidates are not compatible with some collection, production and storage methods or combinations thereof. Further, blood centers using INTERCEPT must have access to those certain devices, blood bags, assays or platelet additive solutions that are compatible with our products.
• Clinical trials are costly and time consuming, may take longer than we expect or may not be completed at all, and their outcomes are uncertain. A failure to generate data in clinical trials to support expanded label claims or to support marketing approvals or certification for our product candidates could materially and adversely affect our business, financial condition, results of operations and growth prospects.
• The red blood cell system is currently in development and may never receive any marketing approvals or CE Certificates of Conformity.